Extended Data Table 1.
Depression Outcomes
| Measure | Ketamine | Placebo | ||||
|---|---|---|---|---|---|---|
| Mean | SD | N with data | Mean | SD | N with data | |
| MADRS total score | ||||||
| Day 0 (pre-infusion) | 25.1 | 8.3 | 20 | 29.9 | 7.0 | 19 |
| Day 1 | 12.7 | 7.6 | 20 | 16.4 | 10.0 | 19 |
| Day 2 | 15.1 | 11.1 | 19 | 17.5 | 11.5 | 20 |
| Day 3 | 17.0 | 10.5 | 19 | 17.2 | 12.0 | 20 |
| Day 5 | 16.9 | 8.0 | 19 | 16.9 | 10.1 | 18 |
| Day 7 | 15.9 | 9.2 | 18 | 18.5 | 10.8 | 19 |
| Day 14 | 16.9 | 10.0 | 19 | 16.2 | 12.5 | 19 |
| HADS total score | ||||||
| Day 0 (pre-infusion) | 22.9 | 4.2 | 20 | 24.6 | 5.6 | 19 |
| Day 1 | 17.8 | 6.6 | 20 | 19.9 | 5.5 | 19 |
| Day 2 | 18.8 | 7.5 | 18 | 21.2 | 5.9 | 20 |
| Day 3 | 19.3 | 6.3 | 19 | 20.8 | 5.4 | 20 |
| Day 5 | 18.3 | 4.8 | 19 | 18.9 | 7.3 | 19 |
| Day 7 | 18.4 | 5.3 | 16 | 19.6 | 8.1 | 19 |
| Day 14 | 16.4 | 7.2 | 19 | 17.2 | 8.5 | 19 |
| n/N in trial | % | n/N in trial | % | |||
| Clinical response on MADRS | ||||||
| Day 0 (pre-infusion) | 0/20 | 0.0 | 0/20 | 0.0 | ||
| Day 1 | 12/20 | 60.0 | 10/20 | 50.0 | ||
| Day 2 | 10/20 | 50.0 | 12/20 | 60.0 | ||
| Day 3 | 9/20 | 45.0 | 10/20 | 50.0 | ||
| Day 5 | 7/19 | 36.8 | 8/19 | 42.1 | ||
| Day 7 | 6/19 | 31.6 | 7/19 | 36.8 | ||
| Day 14 | 8/19 | 42.1 | 11/19 | 57.9 | ||
| Remission on MADRS | ||||||
| Day 0 (pre-infusion) | 1/20 | 5.0 | 0/20 | 0.0 | ||
| Day 1 | 10/20 | 50.0 | 7/20 | 35.0 | ||
| Day 2 | 11/20 | 55.0 | 8/20 | 40.0 | ||
| Day 3 | 8/20 | 40.0 | 8/20 | 40.0 | ||
| Day 5 | 7/19 | 36.8 | 6/19 | 31.6 | ||
| Day 7 | 6/19 | 31.6 | 11/19 | 57.9 | ||
| Day 14 | 8/19 | 42.1 | 9/19 | 47.4 | ||
SD, standard deviation. MADRS, Montgomery–Åsberg Depression Rating Scale. HADS, Hospital Anxiety and Depression Scale. Clinical response is defined as ≥50% reduction in MADRS scores from screening baseline. Remission is defined as MADRS score ≤12.